P/E ratio for Repligen (RGEN)
P/E ratio as of April 2024 (TTM): 75.1
According to Repligen 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 75.1483. At the end of 2022 the company had a P/E ratio of 50.4.
P/E ratio history for Repligen from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 50.4 | -55.48% |
| 2021 | 113 | -32.67% |
| 2020 | 168 | -18.22% |
| 2019 | 206 | 48.11% |
| 2018 | 139 | 179.26% |
| 2017 | 49.7 | -43.56% |
| 2016 | 88.1 | -9.73% |
| 2015 | 97.6 | 23.17% |
| 2014 | 79.2 | 184.52% |
| 2013 | 27.8 | 103.9% |
| 2012 | 13.7 | -143.83% |
| 2011 | -31.1 | -106.64% |
| 2010 | 469 | -1925.79% |
| 2009 | -25.7 | -208.73% |
| 2008 | 23.6 | 372.5% |
| 2007 | 5.00 | -110.68% |
| 2006 | -46.8 | -135.13% |
| 2005 | 133 | -1025.93% |
| 2004 | -14.4 | -11.03% |
| 2003 | -16.2 | -20.14% |
| 2002 | -20.3 | 58.46% |
| 2001 | -12.8 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | 13.7 | -81.84% | 🇺🇸 USA |
 Thermo Fisher Scientific TMO | 35.3 | -53.02% | 🇺🇸 USA |
 General Electric GE | 17.9 | -76.20% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 12.2 | -83.81% | 🇺🇸 USA |
 Sangamo Therapeutics
SGMO | -0.3369 | -100.45% | 🇺🇸 USA |
 Novavax NVAX | -0.5410 | -100.72% | 🇺🇸 USA |
 Neurocrine Biosciences
NBIX | 67.6 | -10.01% | 🇺🇸 USA |
 Bio-Techne TECH | 39.6 | -47.27% | 🇺🇸 USA |
 BioMarin Pharmaceutical BMRN | 116 | 53.93% | 🇺🇸 USA |
 Charles River Laboratories
CRL | 24.0 | -68.09% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.